Rite Aid (RAD) investors had a rough day, with shares cratering 7% after the pharmacy lowered its full-year guidance and reported that it anticipated only $0.04 per share in earnings versus analyst estimates of $0.08 per share. The sell-off felt a little extreme given the stock's stunning turnaround over the past several years.
But then again, competitor Walgreen (WBA) reported better news, indicating that perhaps Rite Aid isn't executing as well in this competitive pharmacy environment.
So, was Rite Aid's sell-off overdone? In the video below, from Thursday's Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their take.
